TMB (Tumor Mutational Burden)

TCR clonality was increased in EBV+ cHL, with trend towards further increase in clonality in HIV+. Through a multiomic approach of a well-characterized, HIV-inclusive cHL cohort from one of the most resource-limited countries in the world, we were able to recapitulate known, and identify novel molecular differences by HIV and EBV status.

As these genes have extra-P-body functions, the score serves as a transcriptomic proxy for P-body component enrichment, not a direct measure of P-body activity. Despite this limitation, it offers a clinically useful tool for risk stratification and mechanistic hypotheses.

The DKK4-based risk prediction model shows moderate predictive value for 1-3-year short-term survival in CRC patients. DKK4 exhibits a stage-specific expression pattern during colorectal tumorigenesis and primarily acts in the precancerous stage of adenoma-carcinoma transition, which makes it a potential specific biomarker for CRC precancerous lesion screening, providing a new molecular target for early CRC screening and intervention.

Importantly, findings from the clinical cohort confirmed that ITGA3 expression was positively correlated with CD206 and PD-L1, and negatively correlated with CD8 and CD19, supporting its role in shaping an immunosuppressive microenvironment. ITGA3 is a promising immune-related biomarker for predicting prognosis and therapeutic response in PDAC and may provide a potential target for personalized treatment strategies.

SMARCAL1 plays a pivotal role in the development of LUAD and exhibits promise in predicting the prognosis and therapeutic efficacy of this malignancy. It is a promising candidate for utilization as a biomarker for LUAD.

Immunotherapy with atezolizumab (1200 mg every 3 weeks [Q3W]) combined with targeted therapy with bevacizumab (600 mg Q3W) was initiated in July 2021.A substantial temporal gap of approximately 21 months followed, after which electroacupuncture-based rehabilitation (5-Hz continuous-wave, stimulating Jiaji acupoints, Zusanli, etc) was started in May 2023. Targeted immunotherapy combined with electroacupuncture may influence neural remodeling by modulating a pro-reparative inflammatory microenvironment, which could potentially support functional reconstruction in patients with spinal metastases. However, there is no direct evidence that immunotherapy accelerates neural recovery, and these observations should be interpreted as hypothesis-generating findings requiring rigorous testing in prospective studies.

Treatment with low-dose Len in transfusion-independent del(5q) MDS reduced the mutational burden of most genes and did not promote the expansion of preexisting clones or AML progression, especially TP53-mutated clones. Early administration of Len in del(5q) MDS patients without TD may be an effective therapeutic approach with a manageable safety profile regarding clonal evolution.

We also highlight clinically relevant biomarkers, including MSI/MMR status, tumor mutational burden, immune contexture, Immunoscore, circulating tumor DNA, microbiome profiles, and spatial or AI-assisted multi-marker models. This review summarizes emerging strategies to enhance therapeutic efficacy in CRC and maps each modality to the tumor-intrinsic or tumor-extrinsic resistance barriers it is most likely to overcome.

This chemokine-based signature provides clinically relevant prognostic stratification in GC and implicates the CXCL8-macrophage axis as a potential therapeutic target.

This ADP-ribosylation-based prognostic model reliably predicts LUAD survival and identifies potential biomarkers for tailored therapy.

P1/2, N=55, Recruiting, University of Chicago | Not yet recruiting --> Recruiting

For early-stage POLE-mutated CRC with favorable prognosis, off-label adjuvant immunotherapy may bring unnecessary toxicity risks. It is necessary to conduct rigorous patient selection, comprehensive risk-benefit evaluation, and close monitoring of organ function during treatment, so as to provide reference for the standardized clinical application of ICIs in this population.